Wednesday, July 8, 2026

pharma · Heart Failure · Atrial Fibrillation · RYTM

Rhythm Pharmaceuticals Netherlands

Rhythm Pharmaceuticals Netherlands clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl HQ
2014 Founded
10 Employees
Public company Type
RYTM · NYSE Ticker
Company details
Status
Public
HQ
BRIGHTLANDS CHEMELOT CAMPUS, VAN ITERSON BUILDING, BURGEMEESTER LEMMENSSTRAAT 352, Geleen, nl
Founded
2014
Employees
10
Programs
73
Drugs
38
Patents
12
Intelligence · Clinical Programs

Rhythm Pharmaceuticals Netherlands projects

14 ClinicalTrials.gov programs sponsored by Rhythm Pharmaceuticals Netherlands.

Rhythm Pharmaceuticals Netherlands has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. CRT with triple site ventricular stimulation

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 3 other completed

    1 trial
  2. Class I or III Antiarrhythmic Medications

    Rhythm Pharmaceuticals Netherlands B.V.

    Atrial Fibrillation

    phase 3 small molecule completed

    1 trial
  3. Coronary artery bypass grafting

    Rhythm Pharmaceuticals Netherlands B.V.

    Ischemic Heart Failure

    phase 3 other completed

    1 trial
  4. Flecainide or Sotalol or Propafenone

    Rhythm Pharmaceuticals Netherlands B.V.

    Paroxysmal Atrial Fibrillation

    phase 3 small molecule completed

    1 trial
  5. Medtronic Talent Stent-Graft-System

    Rhythm Pharmaceuticals Netherlands B.V.

    Aortic Diseases

    phase 3 other completed

    1 trial
  6. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet Biedl Syndrome (BBS)

    phase 3 small molecule completed

    1 trial
  7. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial
  8. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity Associated With Defects in Leptin-melanocortin Pathway

    phase 3 small molecule active

    2 trials
  9. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Pro-opiomelanocortin (POMC) Deficiency Obesity

    phase 3 small molecule completed

    1 trial
  10. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypothalamic Obesity

    phase 3 small molecule active

    3 trials
  11. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Leptin Receptor Deficiency Obesity

    phase 3 small molecule completed

    1 trial
  12. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Obesity

    phase 3 small molecule active

    1 trial
  13. Setmelanotide 2 mg

    Rhythm Pharmaceuticals Netherlands B.V.

    Bardet-Biedl Syndrome

    phase 3 small molecule completed

    1 trial
  14. Ventricular Assist Device System

    Rhythm Pharmaceuticals Netherlands B.V.

    Heart Failure

    phase 3 other completed

    1 trial

Frequently asked questions

How many clinical projects does Rhythm Pharmaceuticals Netherlands have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.